Pertuzumab for the treatment of breast cancer: a safety review. Issue 6 (2nd June 2016)

• Record Type: Journal Article
• Authors: Gao, Jennifer; Swain, Sandra M.
• Is Part Of: Expert opinion on drug safety. Volume 15:Issue 6(2016)
• Page Start: 853
• Page End: 863
• Publication Date: 2016-06-02
• Subjects: Pertuzumab -- trastuzumab -- monoclonal antibody -- HER2 -- CLEOPATRA -- TRYPHAENA -- NeoSphere; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1517/14740338.2016.1167185
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Introduction: Approximately twenty to thirty percent of newly diagnosed breast cancers are human epidermal growth factor receptor 2 (HER2) positive. The use of trastuzumab, and more recently pertuzumab, has significantly improved the progression free survival (PFS) and overall survival (OS) in this patient population. However, pertuzumab has side effects that can impact treatment tolerability and quality of life. Areas covered: This review describes the safety and tolerability of pertuzumab, a monoclonal antibody targeted at HER2 approved by the United States Food and Drug Administration (FDA) for use in the neoadjuvant and first line metastatic settings. Expert opinion: The combination of trastuzumab, pertuzumab, and chemotherapy is approved in the neoadjuvant and first line metastatic settings and should be strongly considered by providers. Further studies are needed to look at side effect prevention, novel pertuzumab containing regimens, and re-treating patients with pertuzumab.